Skip to main content
. Author manuscript; available in PMC: 2007 Dec 8.
Published in final edited form as: Cancer Res. 2007 May 1;67(9):4173–4181. doi: 10.1158/0008-5472.CAN-06-3128

Figure 2.

Figure 2

Papilloma development in DMBA-initiated, TPA-promoted CD34KO mice. Seven-week-old CD34KO and WT mice were first initiated with subtumorigenic doses of DMBA and then promoted for 20 weeks with three applications per week of TPA in the standard two-stage mouse skin carcinogenesis regimen. Papillomas were counted weekly. A and B, mice were initiated with 200 nmol DMBA and then promoted thrice weekly with 4 μg TPA for 20 wks. A, average number of tumors per mouse. B, incidence of papillomas. C and D, CD34KO and WT mice were initiated with 400 nmol DMBA and then promoted thrice weekly with 5 μg TPA for 20 wks. C, average number of tumors per mouse. D, incidence of papillomas. E, mice were initiated with either 200 or 400 nmol DMBA, and keratinocytes were harvested 20 h later for DNA isolation and 32P-postlabeling identification of DMBADE DNA adducts. Top, DNA adducts for WT at 200 and 400 nmol; bottom, DNA adducts for CD34KO mice at 200 and 400 nmol. Syn-dAdo and anti-dAdo adducts are identified as I (retention time, 0.96 min) and II (retention time, 1.05 min), respectively.